Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa.

OBJECTIVES This study evaluated the potential of DNase, alginate lyase (AlgL) and N-acetylcysteine (NAC) in enhancing the in vitro bactericidal activity of conventional (free) and vesicle-entrapped (liposomal) gentamicin, amikacin and tobramycin. METHODS The MICs and biofilm eradication for two clinical isolates of Pseudomonas aeruginosa (a mucoid strain and a non-mucoid strain) were determined in the presence and absence of AlgL. The co-activity of aminoglycosides with DNase and/or AlgL against endogenous P. aeruginosa in cystic fibrosis (CF) sputum was also measured. The inhibitory effects of mucin in the presence and absence of the mucolytic agent NAC on aminoglycosidic activity were also examined. RESULTS The MIC values of the liposomal aminoglycosides were similar to or lower than those of free aminoglycosides. Biofilm formation increased the bactericidal concentrations of these drugs by 8- to 256-fold and treatment with AlgL improved killing of the mucoid strain. The activity of some aminoglycosides against the sputum was increased by the addition of DNase or AlgL (P < 0.05), and was increasingly evident with concurrent DNase and AlgL administration. Addition of mucin inhibited liposomal aminoglycosidic activity (up to 32-fold) evidently more than the free aminoglycosides (up to 8-fold). The addition of NAC did not improve activity significantly (P > 0.05). Tobramycin was the most effective aminoglycoside to reduce biofilms and sputum. CONCLUSIONS Liposomal aminoglycosides do not fare better than conventional forms. The co-administration of DNase and AlgL is essential for enhanced activity in reducing biofilm growth and sputum bacterial counts. While mucin retards bactericidal activity, NAC does not improve aminoglycosidic activity.

[1]  J. Carlsson,et al.  Interactions between human neutrophils and mucin-coated surfaces , 2009, Journal of materials science. Materials in medicine.

[2]  P. Robinson.  Dornase alfa in early cystic fibrosis lung disease , 2002, Pediatric pulmonology.

[3]  G. Pier,et al.  Inhibition of adherence of mucoid Pseudomonas aeruginosa by alginase, specific monoclonal antibodies, and antibiotics , 1993, Infection and immunity.

[4]  J. Elborn.  How can we prevent multisystem complications of cystic fibrosis? , 2007, Seminars in respiratory and critical care medicine.

[5]  P. Janmey,et al.  Elastic contributions dominate the viscoelastic properties of sputum from cystic fibrosis patients. , 2004, Biophysical chemistry.

[6]  T. Welte,et al.  Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? , 2006, The Journal of antimicrobial chemotherapy.

[7]  E. Alton,et al.  The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro , 1998, Gene Therapy.

[8]  C. Nast,et al.  Functional role of mucoid exopolysaccharide (alginate) in antibiotic-induced and polymorphonuclear leukocyte-mediated killing of Pseudomonas aeruginosa , 1991, Infection and immunity.

[9]  S. Antimisiaris,et al.  Liposomes for drug delivery to the lungs by nebulization. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[10]  V. Waters,et al.  Multidrug–resistant organisms in cystic fibrosis: management and infection–control issues , 2006, Expert review of anti-infective therapy.

[11]  R. Dinwiddie.  Anti-inflammatory therapy in cystic fibrosis. , 2005, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[12]  R. Mrsny,et al.  Addition of a bacterial alginate lyase to purulent CF sputum in vitro can result in the disruption of alginate and modification of sputum viscoelasticity. , 1994, Pulmonary pharmacology.

[13]  B. Ramsey,et al.  Macromolecular mechanisms of sputum inhibition of tobramycin activity , 1995, Antimicrobial agents and chemotherapy.

[14]  M. Maurin,et al.  Aminoglycoside nephrotoxicity. , 2004, Current drug targets. Infectious disorders.

[15]  Abdelwahab Omri,et al.  Mechanism of Enhanced Activity of Liposome-Entrapped Aminoglycosides against Resistant Strains of Pseudomonas aeruginosa , 2006, Antimicrobial Agents and Chemotherapy.

[16]  S. Smedt,et al.  Structural alterations of gene complexes by cystic fibrosis sputum. , 2001, American journal of respiratory and critical care medicine.

[17]  D. Rogers.  Mucoactive agents for airway mucus hypersecretory diseases. , 2007, Respiratory care.

[18]  S. Smedt,et al.  Cystic fibrosis sputum: a barrier to the transport of nanospheres. , 2000, American journal of respiratory and critical care medicine.

[19]  M. D. Williams,et al.  Should aminoglycoside antibiotics be abandoned? , 2000, American journal of surgery.

[20]  R. Ramphal,et al.  The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum. , 1988, The Journal of antimicrobial chemotherapy.

[21]  C. Nast,et al.  Effects of alginase on the natural history and antibiotic therapy of experimental endocarditis caused by mucoid Pseudomonas aeruginosa , 1992, Infection and immunity.

[22]  I. Stelmach,et al.  Long-Term Benefits of Inhaled Tobramycin in Children with Cystic Fibrosis: First Clinical Observations from Poland , 2007, Respiration.

[23]  N. Schiller,et al.  Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms , 2006, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[24]  N. Høiby.  Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies. , 2002, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[25]  N. Schiller,et al.  Alginate Lyase Promotes Diffusion of Aminoglycosides through the Extracellular Polysaccharide of Mucoid Pseudomonas aeruginosa , 1998, Antimicrobial Agents and Chemotherapy.

[26]  R. Langer,et al.  Lipid-alginate interactions render changes in phospholipid bilayer permeability. , 1991, Biochimica et biophysica acta.

[27]  M. Boyle.  Adult cystic fibrosis. , 2007, JAMA.

[28]  Jay X. Tang,et al.  Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[29]  Aseem Kumar,et al.  Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. , 2007, The Journal of antimicrobial chemotherapy.

[30]  James R. Smith,et al.  Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. , 2007, Pulmonary pharmacology & therapeutics.

[31]  N. Høiby,et al.  Effect of aerosolized rhDNase (Pulmozyme®) on pulmonary colonization in patients with cystic fibrosis , 2006, Acta paediatrica.

[32]  P. Janmey,et al.  Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. , 1994, Science.

[33]  B. Rubin,et al.  The Role of DNA and Actin Polymers on the Polymer Structure and Rheology of Cystic Fibrosis Sputum and Depolymerization by Gelsolin or Thymosin Beta 4 , 2007, Annals of the New York Academy of Sciences.

[34]  D. Wozniak,et al.  Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis , 2005, Molecular microbiology.

[35]  E. Nash,et al.  Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. , 2009, The Cochrane database of systematic reviews.

[36]  J. Hupp,et al.  Mucin–Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance , 2006, Molecular microbiology.

[37]  Abdelwahab Omri,et al.  Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients. , 2005, The Journal of antimicrobial chemotherapy.

[38]  T. Murray,et al.  Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients , 2007, Current opinion in pediatrics.

[39]  B. Rubin.  Mucus structure and properties in cystic fibrosis. , 2007, Paediatric respiratory reviews.

[40]  T. Yotsuyanagi,et al.  Application of alginate gel as a vehicle for liposomes. I. Factors affecting the loading of drug-containing liposomes and drug release. , 1996, Chemical & pharmaceutical bulletin.

[41]  Bruce A. Stanton,et al.  Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. , 2008, Pulmonary pharmacology & therapeutics.

[42]  Richard Phipps,et al.  The Pseudomonas aeruginosa Quorum-Sensing Molecule N-(3-Oxododecanoyl)Homoserine Lactone Contributes to Virulence and Induces Inflammation In Vivo , 2002, Journal of bacteriology.

[43]  R. D. De Lisle,et al.  Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[44]  A. Daugherty,et al.  Distribution of DNA and alginate in purulent cystic fibrosis sputum: implications to pulmonary targeting strategies. , 1996, Journal of drug targeting.

[45]  C. Metcalfe,et al.  Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. , 2002, American journal of respiratory and critical care medicine.